| scholarly article | Q13442814 |
| P50 | author | Steven R Alberts | Q88846398 |
| P2093 | author name string | S Gill | |
| M Wiesenfeld | |||
| J Kugler | |||
| P Steen | |||
| T R Fitch | |||
| P Schaefer | |||
| R F Morton | |||
| N R Foster | |||
| G P Kim | |||
| P2860 | cites work | Increased expression of NF-kappa B subunits in human pancreatic cancer cells | Q40565497 |
| Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome | Q43715004 | ||
| Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer | Q44565471 | ||
| Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer | Q44915315 | ||
| Phase II trial of bortezomib for patients with advanced renal cell carcinoma | Q45057193 | ||
| An analysis of variance test for normality (complete samples) | Q57253423 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors | Q33151848 | ||
| Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies | Q33345317 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study | Q33358394 | ||
| 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer | Q33950784 | ||
| Development of the proteasome inhibitor Velcade (Bortezomib). | Q34327233 | ||
| Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer | Q34754670 | ||
| P433 | issue | 10 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| pancreatic adenocarcinoma | Q18556189 | ||
| metastatic pancreatic adenocarcinoma | Q19000961 | ||
| P304 | page(s) | 1654-1661 | |
| P577 | publication date | 2005-08-05 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study | |
| P478 | volume | 16 |
| Q33375650 | A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium |
| Q33394153 | A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). |
| Q39958680 | Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin |
| Q33391857 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. |
| Q37326210 | Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. |
| Q36529784 | Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. |
| Q52647259 | Chemotherapy and radiotherapy for advanced pancreatic cancer. |
| Q24240739 | Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer |
| Q24245085 | Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer |
| Q37136598 | Clinical development of novel proteasome inhibitors for cancer treatment |
| Q34372977 | Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma |
| Q37344586 | Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. |
| Q38352184 | Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. |
| Q38258843 | Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials |
| Q36989921 | Emerging drugs for biliary cancer |
| Q36866617 | Emerging drugs for the treatment of pancreatic cancer |
| Q28533949 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development |
| Q64064242 | Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells |
| Q34976755 | Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials |
| Q37017342 | Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials |
| Q36758436 | Molecular mechanisms of pancreatic cancer and potential targets of treatment |
| Q37996435 | NF-κB as a target for pancreatic cancer therapy. |
| Q38002469 | New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies |
| Q37614590 | Novel agents for the treatment of adenocarcinoma of the pancreas |
| Q37107622 | Novel therapies for pancreatic cancer: setbacks and progress |
| Q36623071 | Pancreatic cancer: a review of recent advances |
| Q33899954 | Pancreatic cancer: molecular pathogenesis and new therapeutic targets |
| Q42098281 | Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer |
| Q37327280 | Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. |
| Q52720471 | Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. |
| Q37449396 | Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer |
| Q46033964 | Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. |
| Q50304177 | Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer |
| Q35076238 | Systemic therapy for metastatic pancreatic adenocarcinoma |
| Q36678582 | Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status |
| Q33899923 | Targeted therapies for pancreatic cancer |
| Q37004739 | Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. |
| Q37709559 | The development and pharmacology of proteasome inhibitors for the management and treatment of cancer |
| Q38211076 | The role of inflammation in pancreatic cancer |
| Q33916030 | The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. |
| Q47420926 | Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. |
Search more.